4 October 2002 News Update
Pharmac and GlaxoSmithKline are still negotiating the funding level of Flixotide, after passing the October 1 deadline. Meanwhile Flixotide remains fully subsidised.
GSK medical director Dr Ian Griffiths says he believes Flixotide is a safer and more effective medicine than Becotide and Becloforte. These inhalers contained CFCs, and are being phased out.
A recent AC Nielsen survey shows 72% pf previous Becotide and Becloforte users have better control of their asthma having switched to Flixotide.
Back to welcome page
Back to news archives
Complete this month's questionnaire to qualify for extra Continuing Education credits. Click here For the answers to last month's quiz click here.
Click here for entry details for the 2003 Zuellig Pharma/Pharmacy Today Awards and to find out last year's winners. Also view and purchase photos of the 2002 Awards.
For the leading stories in our latest issue of Pharmacy Today magazine visit our welcome page.
To subscribe to Pharmacy Today, or to purchase The Beauty Manual or The Pharmacy Healthcare Handbook click here.
Consumer Health Information
New Zealand Doctor Online
Home II Conferences II Contact Us II Continuing Education II Magazine Profile II Monthly News Archives
Weekly News Archives II II Readership II Search Magazine Archives